MANNKIND CORP Additional Paid in Capital, Common Stock
MANNKIND CORP (MNKD) had Additional Paid in Capital, Common Stock of $3.16 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-05
- 2026-06-30: Additional Paid in Capital, Common Stock $3.16B.
- 2026-03-31: Additional Paid in Capital, Common Stock $3.15B.
- 2025-12-31: Additional Paid in Capital, Common Stock $3.14B.
- 2025-09-30: Additional Paid in Capital, Common Stock $3.13B.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $3.16B 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $3.15B 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $3.14B 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $3.13B 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $3.13B 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $3.13B 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $3.12B 10-K · filed 2026-02-26 | |
| 2024-09-30 | $3.00B 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $2.99B 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $2.99B 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $2.98B 10-K · filed 2025-02-26 | |
| 2023-09-30 | $2.98B 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $2.97B 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $2.97B 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $2.96B 10-K · filed 2024-02-27 | |
| 2022-09-30 | $2.96B 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $2.94B 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $2.92B 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $2.92B 10-K · filed 2023-02-23 | |
| 2021-09-30 | $2.91B 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $2.91B 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $2.89B 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $2.87B 10-K · filed 2022-02-24 | |
| 2020-09-30 | $2.83B 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $2.83B 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $2.80B 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $2.80B 10-K · filed 2021-02-25 | |
| 2019-09-30 | $2.79B 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $2.77B 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $2.77B 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $2.76B 10-K · filed 2020-02-25 | |
| 2018-09-30 | $2.72B 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $2.70B 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $2.66B 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $2.64B 10-K · filed 2019-02-26 | |
| 2017-09-30 | $2.57B 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $2.57B 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $2.55B 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $2.55B 10-K · filed 2018-02-27 | $2.55B 10-K · filed 2017-03-16 |
| 2016-09-30 | $2.55B 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $2.55B 10-Q/A · filed 2016-08-10 | |
| 2016-03-31 | $2.51B 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $2.51B 10-K · filed 2017-03-16 | |
| 2015-09-30 | $2.46B 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $2.43B 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $2.42B 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $2.42B 10-K · filed 2016-03-15 | |
| 2014-09-30 | $2.41B 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $2.37B 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $2.36B 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $2.26B 10-K · filed 2015-03-02 | |
| 2013-09-30 | $2.07B 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $2.04B 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $2.00B 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $1.99B 10-K · filed 2014-03-03 | |
| 2012-09-30 | $1.77B 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $1.76B 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $1.69B 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $1.62B 10-K · filed 2013-03-18 | |
| 2011-09-30 | $1.62B 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $1.61B 10-Q · filed 2011-08-04 | |
| 2010-12-31 | $1.59B 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |